271 related articles for article (PubMed ID: 29623583)
41. [Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases].
Selmes G; Ferron G; Filleron T; Querleu D; Mery E
Gynecol Obstet Fertil; 2015 Oct; 43(10):659-64. PubMed ID: 26433315
[TBL] [Abstract][Full Text] [Related]
42. The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
Rudaitis V; Mikliusas V; Januska G; Jukna P; Mickys U; Janavicius R
Eur J Obstet Gynecol Reprod Biol; 2020 Apr; 247():26-31. PubMed ID: 32059136
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
44. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
Blok F; Roes EM; van Leenders GJ; van Beekhuizen HJ
BMC Cancer; 2016 Jan; 16():18. PubMed ID: 26768420
[TBL] [Abstract][Full Text] [Related]
45. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
Ricciardi E; Tomao F; Aletti G; Bazzurini L; Bocciolone L; Boveri S; Landoni F; Lapresa MT; Maruccio M; Parma G; Peccatori F; Petrella MC; Zanagnolo V; Colombo N; Maggioni A
Anticancer Res; 2017 Sep; 37(9):5241-5248. PubMed ID: 28870960
[TBL] [Abstract][Full Text] [Related]
46. Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
Grandi G; Caroli M; Alboni C; Cortesi L; Toss A; Barbieri E; Botticelli L; Facchinetti F
Fam Cancer; 2020 Oct; 19(4):291-295. PubMed ID: 32328861
[TBL] [Abstract][Full Text] [Related]
47. [Fallopian tube: the dark face of pelvic carcinogenesis].
Watkin E; Devouassoux-Shisheboran M
Ann Pathol; 2011 Oct; 31(5):345-52. PubMed ID: 21982240
[TBL] [Abstract][Full Text] [Related]
48. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
49. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
Seidman JD
Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
[TBL] [Abstract][Full Text] [Related]
50. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
Harmsen MG; Piek JMJ; Bulten J; Casey MJ; Rebbeck TR; Mourits MJ; Greene MH; Slangen BFM; van Beurden M; Massuger LFAG; Hoogerbrugge N; de Hullu JA
Cancer; 2018 Mar; 124(5):952-959. PubMed ID: 29315498
[TBL] [Abstract][Full Text] [Related]
51. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
[TBL] [Abstract][Full Text] [Related]
52. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
53. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
[TBL] [Abstract][Full Text] [Related]
54. Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.
Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA;
Fam Cancer; 2017 Oct; 16(4):461-469. PubMed ID: 28285341
[TBL] [Abstract][Full Text] [Related]
55. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.
Pla-Juher H; Pardo M; Izquierdo ÀJ; Darder E; Carbó A; Munté E; Torres-Esquius S; Balmaña J; Lázaro C; Brunet JM; Barretina-Ginesta MP
Clin Transl Oncol; 2024 Apr; 26(4):1033-1037. PubMed ID: 37682500
[TBL] [Abstract][Full Text] [Related]
56. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
[TBL] [Abstract][Full Text] [Related]
57. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
George SH; Milea A; Shaw PA
Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
[TBL] [Abstract][Full Text] [Related]
58. LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
Schmoeckel E; Odai-Afotey AA; Schleißheimer M; Rottmann M; Flesken-Nikitin A; Ellenson LH; Kirchner T; Mayr D; Nikitin AY
Mod Pathol; 2017 Sep; 30(9):1241-1250. PubMed ID: 28664938
[TBL] [Abstract][Full Text] [Related]
59. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
Bijron JG; Seldenrijk CA; Zweemer RP; Lange JG; Verheijen RH; van Diest PJ
Am J Surg Pathol; 2013 Aug; 37(8):1123-30. PubMed ID: 23648462
[TBL] [Abstract][Full Text] [Related]
60. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.
Carlson JW; Miron A; Jarboe EA; Parast MM; Hirsch MS; Lee Y; Muto MG; Kindelberger D; Crum CP
J Clin Oncol; 2008 Sep; 26(25):4160-5. PubMed ID: 18757330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]